Research programme: mRNA based protein replacement therapies - BioNTech/Genevant Sciences
Latest Information Update: 28 Aug 2022
At a glance
- Originator BioNTech; Genevant Sciences
- Class Proteins; RNA
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Unspecified in Germany (Parenteral)
- 28 Aug 2022 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 10 Jul 2018 BioNTech and Genevant Sciences plan a phase I clinical trial in the second half of 2020